Abstract
Antiplatelet is the cornerstone therapy for patient with coronary artery disease. Several comorbidities can influence the efficacy and safety of antiplatelet agent. Diabetes mellitus is characterized by increased platelet reactivity and reduced response to antiplatelet. Elderly patients have both reduced response to antiplatelet and increased risk of bleeding. Patients with renal dysfunction also had decreased efficacy of antiplatelet accompanied with increased risk of bleeding. In patients with atrial fibrillation, the concomitant use of anticoagulant with antiplatelet poses an increased risk of bleeding. In patients with these comorbidities, caution should be stressed in selecting the best regimen of antiplatelet which translates the most optimal efficacy while minimizing the risk of adverse events. In this review, we will discuss the platelet changes in these comorbidities, current evidence of antiplatelet usage in these group of patients and current recommendation.
Keywords: Antiplatelet, coronary artery disease, diabetes mellitus, elderly, renal dysfunction, atrial fibrillation.
Current Pharmaceutical Design
Title:Antiplatelet for Coronary Artery Disease in Specific Condition “No Size Fits All”
Volume: 24 Issue: 4
Author(s): Benny M. Setiadi, Beny Hartono, Adhitia B. Prakoso, Anggia C. Lubis, Reza M. Munandar and Muhammad Munawar*
Affiliation:
- Binawaluya Cardiac Center, Jakarta,Indonesia
Keywords: Antiplatelet, coronary artery disease, diabetes mellitus, elderly, renal dysfunction, atrial fibrillation.
Abstract: Antiplatelet is the cornerstone therapy for patient with coronary artery disease. Several comorbidities can influence the efficacy and safety of antiplatelet agent. Diabetes mellitus is characterized by increased platelet reactivity and reduced response to antiplatelet. Elderly patients have both reduced response to antiplatelet and increased risk of bleeding. Patients with renal dysfunction also had decreased efficacy of antiplatelet accompanied with increased risk of bleeding. In patients with atrial fibrillation, the concomitant use of anticoagulant with antiplatelet poses an increased risk of bleeding. In patients with these comorbidities, caution should be stressed in selecting the best regimen of antiplatelet which translates the most optimal efficacy while minimizing the risk of adverse events. In this review, we will discuss the platelet changes in these comorbidities, current evidence of antiplatelet usage in these group of patients and current recommendation.
Export Options
About this article
Cite this article as:
Setiadi M. Benny, Hartono Beny , Prakoso B. Adhitia , Lubis C. Anggia , Munandar M. Reza and Munawar Muhammad *, Antiplatelet for Coronary Artery Disease in Specific Condition “No Size Fits All”, Current Pharmaceutical Design 2018; 24 (4) . https://dx.doi.org/10.2174/1381612824666180209111212
DOI https://dx.doi.org/10.2174/1381612824666180209111212 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Molecular Hydrogen: New Antioxidant and Anti-inflammatory Therapy for Rheumatoid Arthritis and Related Diseases
Current Pharmaceutical Design The Role of Polyunsaturated Fatty Acids (PUFA) in the Treatment of Dyslipidemias
Current Pharmaceutical Design Association between Single-nucleotide Polymorphisms of RXRG and Genetic Susceptibility to Type 2 Diabetes in South China
Current Molecular Medicine Momordica charantia and Type 2 Diabetes: From in vitro to Human Studies
Current Diabetes Reviews Withdrawal Notice: Characterization of Glyoxal Modified LDL: Role in the Generation of Circulating Autoantibodies in Type 2 Diabetes Mellitus and Coronary Artery Disease
Current Drug Targets Lipoprotein(a) Management: Pharmacological and Apheretic Treatment
Current Medicinal Chemistry SIRT1, a Calorie Restriction Mimetic, in a New Therapeutic Approach for Type 2 Diabetes Mellitus and Diabetic Vascular Complications
Endocrine, Metabolic & Immune Disorders - Drug Targets Amyloid Forming Proteases: Therapeutic Targets for Alzheimers Disease
Current Pharmaceutical Design Drug Hypersensitivity: Epidemiology and Risk Factors
Current Pharmaceutical Design Vitamin D Biology in Heart Failure: Molecular Mechanisms and Systematic Review
Current Drug Targets Homocysteine and Folate Therapy in Dialysis Patients
Letters in Drug Design & Discovery Incidence and Prevalence of Hypothyroidism in Patients Affected by Chronic Heart Failure: Role of Amiodarone
Endocrine, Metabolic & Immune Disorders - Drug Targets Update on the Role of Neutrophils in Atherosclerotic Plaque Vulnerability
Current Drug Targets Tuberculous Lymphadenitis in Southern Italy: Clinical Aspects and Treatment Perspectives
Anti-Infective Agents Choosing a Revascularization Strategy in Patients with Diabetes and Stable Coronary Artery Disease: A Complex Decision
Current Cardiology Reviews Gut Involvement in NOD Mouse Diabetes
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Anti-islet Cell Antibodies in a Sample of Egyptian Females with Gestational Diabetes and its Relation to Development of Type 1 Diabetes Mellitus
Current Diabetes Reviews Carotenoids of Microalgae Used in Food Industry and Medicine
Mini-Reviews in Medicinal Chemistry The Heme Oxygenase/Biliverdin Reductase Pathway in Drug Research and Development
Current Drug Metabolism Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery